Menu
Close
.svg)
Over the past several months, I've been conducting qualitative research interviews and focus groups with physicians who treat and patients living with advanced prostate cancer.
Of all the therapeutic areas within oncology I've had the opportunity to study throughout my career, prostate cancer is probably the one I know best. I've interviewed hundreds of men across every stage of the disease, from those newly diagnosed with localized cancer to those facing metastatic disease, along with countless spouses and care partners. Every interview, focus group and advisory board reminds me how rapidly the therapeutic armamentarium continues to evolve. New therapies emerge, treatment sequencing shifts, and physicians continually rethink where and when to introduce the latest innovations.
One therapy, in particular, kept surfacing in recent conversations: Pluvicto.
What I noted wasn't simply that physicians were talking about it. It was how they were talking about it. The conversations were rarely about whether the drug works. Instead, they centered on much more practical questions. When should Pluvicto be introduced? Should it continue to be reserved for men whose disease has progressed after androgen receptor pathway inhibitors and chemotherapy, or is there value in moving it earlier? Which patients are most likely to benefit? How should PSMA-PET imaging influence treatment decisions? And perhaps most revealingly, how do you refer a patient into a treatment pathway that bears little resemblance to prescribing an oral oncology medication?
The patients and their care partners described a different side of the story. Many viewed Pluvicto as a promising option they hoped to reach before their disease progressed further. Others wondered whether recent changes in the treatment landscape might make them eligible sooner. Those conversations have become even more relevant following the FDA's recent decision to expand Pluvicto's indication into PSMA-positive metastatic hormone-sensitive prostate cancer. Based on the 1,144-patient PSMAddition study, the approval allows physicians to offer the therapy much earlier in the course of disease, before patients develop castration-resistant disease, and nearly doubles the population eligible to receive it. Like many important advances in oncology, the story is no longer simply whether a therapy works, but where it fits in.
Those conversations sent me down an unexpected path of curiosity.
Pluvicto belongs to a category of medicines known as radiopharmaceuticals. Until recently, I knew the term, but not much beyond it. The more I explored, however, the more I realized that radiopharmaceuticals represent far more than another promising class of cancer drugs. They are creating an entirely new "neighborhood" within the pharmaceutical industry, complete with its own vocabulary, infrastructure, investment patterns, scientific meetings and career opportunities. I thought to myself that if I had spent decades in the industry without fully appreciating what was going on here, there were probably many others who would benefit from taking a closer look.
Every emerging field develops its own vocabulary, and radiopharmaceuticals are no exception. Within a few days of investigating this neighborhood, I found myself encountering an entirely new lexicon: radioligand therapies (RLTs), alpha emitters, beta emitters, dosimetry, isotope half-life, PSMA, actinium-225, lutetium-177, lead-212 and theranostics.
Initially, the terminology felt intimidating. Gradually, however, each concept became another piece of a much larger picture.
At their simplest, radiopharmaceuticals combine two components into a single medicine. The first is a targeting molecule that recognizes a specific biological marker expressed on cancer cells. The second is a radioactive isotope attached to that molecule. Rather than blocking a signaling pathway or activating the immune system, the therapy delivers radiation directly to the tumor itself. In the case of Pluvicto, a prime example, the targeting molecule binds to prostate-specific membrane antigen (PSMA), a protein expressed on many prostate cancer cells, while the radioactive isotope lutetium-177 delivers localized beta radiation to destroy those cells.
Researchers are now investigating a growing range of radioactive "payloads." Lutetium-177 is a beta emitter, meaning its radiation travels several millimeters through tissue. Newer therapies are increasingly exploring alpha emitters, including actinium-225 and lead-212. Alpha particles travel much shorter distances but deliver substantially greater energy, potentially creating more lethal double-stranded DNA damage while reducing radiation exposure to surrounding healthy tissue. Whether alpha emitters ultimately prove superior across different tumor types remains an active area of investigation, but the pace of innovation has been remarkable.
Perhaps the most elegant concept in the field of radiopharmaceuticals is theranostics, although the idea itself is surprisingly straightforward. A diagnostic imaging agent first determines whether a patient's tumor expresses the appropriate molecular target. If it does, a closely related therapeutic radiopharmaceutical can then deliver treatment to those same cells. Diagnosis and treatment become linked by the same underlying biology. It is one of the clearest examples of precision medicine in practice, and it also helps explain why imaging has become such an integral part of the radiopharmaceutical ecosystem.
By this point, the conversations I'd been hearing from physicians suddenly made much more sense. Pluvicto wasn't simply another oncology medication in the treatment sequence. It required diagnostic imaging, nuclear medicine expertise, specialized manufacturing, carefully coordinated scheduling and multidisciplinary care. Physicians weren't merely discussing another drug. They were learning to work through an entirely different model of delivering cancer treatment.
One lesson I've learned over the years is that when multiple pharmaceutical companies are making major, independent investments in the same technology, it's worth paying attention. Individual acquisitions can always be explained away. Entire industries moving in the same direction usually signal something more fundamental. And when you take a closer look, that pattern is clearly happening in the radiopharmaceuticals business.
Novartis established itself as an early commercial leader with Lutathera (approved in 2018 for gastroenteropancreatic neuroendocrine tumors) and Pluvicto. Bristol Myers Squibb acquired RayzeBio. AstraZeneca purchased Fusion Pharmaceuticals. Eli Lilly acquired POINT Biopharma and has continued investing in companies such as Ratio Therapeutics. Sanofi entered the field through its partnership with Orano Med, while companies including Aktis Oncology, AdvanCell, Telix Pharmaceuticals, ITM Isotope Technologies Munich, Perspective Therapeutics and Artbio continue to advance increasingly ambitious pipelines spanning prostate cancer, neuroendocrine tumors, breast cancer, lung cancer, glioblastoma, ovarian cancer and many other solid tumors.
What fascinated me, however, was that the industry's ambitions increasingly appear to extend beyond developing the next successful therapy. They are beginning to encompass something much larger.
The clearest illustration arrived just a few days ago, when Curium announced its acquisition of Lantheus in a transaction valued at up to $8 billion. At first glance, it looked like another large acquisition in an increasingly active sector. Looking more closely, however, the strategic rationale was far more revealing than the price tag. Curium brings expertise in isotope production and manufacturing. Lantheus contributes Pylarify, the leading PSMA-PET imaging agent that helps identify which prostate cancer patients are candidates for radioligand therapy, along with an established commercial presence in diagnostic imaging. The combined company spans much of the radiopharmaceutical value chain, from isotope production to diagnostic imaging to therapeutic radioligands. That is not simply portfolio expansion. It is ecosystem building.
Viewed together, these transactions imply that companies are competing on a very different playing field than they have in traditional pharmaceuticals. Historically, competitive advantage has been defined by intellectual property, compelling clinical evidence, commercial execution and market access. Those capabilities remain essential, but radiopharmaceuticals introduce entirely new sources of competitive advantage. Companies are now investing in isotope production, manufacturing capacity, imaging platforms and specialized supply chains because those capabilities may ultimately prove just as valuable as the molecule itself.
The science is evolving just as quickly as the business strategy. Researchers are exploring whether beta emitters such as lutetium-177 or alpha emitters such as actinium-225 and lead-212 will prove more effective across different tumor types. New indications continue to emerge. Pluvicto is now moving earlier in prostate cancer, while companies including ITM, Orano Med and others are advancing late-stage programs in neuroendocrine tumors and additional solid cancers. The investment activity suggests that the industry increasingly views radiopharmaceuticals not as a niche modality, but as another foundational platform in precision oncology.
As I continued reading, I realized that radiopharmaceuticals are unusual because they change far more than the medicine itself. They change the operating model.
A conventional oncology therapy can often be manufactured, packaged, distributed, stocked and prescribed through processes that have been refined over decades. Radiopharmaceuticals introduce an entirely different set of constraints. Radioactive isotopes begin decaying the moment they are produced. Their half-life influences manufacturing schedules, quality testing, transportation, treatment appointments and inventory management. A delay measured in hours, rather than days, can materially affect how a therapy is delivered.
That reality creates commercial challenges that most pharmaceutical organizations rarely encounter. Success depends not only on HCP awareness or payer coverage, but also on reliable isotope production, specialized manufacturing facilities, nuclear pharmacies, PET imaging capacity, hospital scheduling and multidisciplinary coordination among oncologists, nuclear medicine physicians, radiologists and pharmacists. Commercial strategy, medical affairs, manufacturing, operations and market access become tightly interconnected in ways that most organizational charts were never designed to accommodate.
The industry has already experienced what happens when those pieces fail to align. Shortly after Pluvicto's launch, manufacturing constraints contributed to supply shortages that temporarily limited patient access despite strong clinical demand. Other companies developing alpha-emitting therapies have encountered shortages of actinium-225, a radioisotope that remains in limited global supply. These are not simply manufacturing problems. They are reminders that building a successful radiopharmaceutical business requires much more than just discovering an effective therapy.
One of the signals I often watch when an emerging field begins to mature is where people choose to gather. Scientific meetings are more than venues for presenting data. They are places where new professional communities begin to take shape.
The annual meetings of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have grown into important forums that now attract far more than nuclear medicine specialists. Pharmaceutical executives, commercial leaders, business development teams, investors, manufacturing experts and health system leaders increasingly attend these meetings because they recognize that radiopharmaceuticals sit at the intersection of multiple disciplines. Dedicated conferences focused on theranostics, molecular imaging and radiopharmaceutical development continue to expand, reflecting the growing breadth of the field.
Perhaps the most telling indicator, however, is the demand for talent. As several recent industry reports have noted, including one last year in STAT+, the field faces shortages of radiochemists, nuclear medicine physicians, radiopharmacists, medical physicists and professionals with expertise in isotope manufacturing and radioligand development. Even experienced pharmaceutical companies are discovering that these skills cannot be hired overnight. That should sound familiar. Every significant technological shift creates demand long before educational programs and career pathways have time to respond.
For professionals working in commercial strategy, marketing, medical affairs or I&A, this presents an opportunity as much as a challenge. Understanding radiopharmaceuticals does not require becoming a nuclear medicine expert. It does require recognizing that this is a rapidly evolving therapeutic platform with its own scientific language, commercial dynamics and competitive landscape. Those who invest the time to understand it today are likely to find themselves well positioned as the field continues to expand.
When I first heard Pluvicto mentioned repeatedly during HCP and patient interviews, I assumed I was simply observing the arrival of another important oncology therapy. I didn't expect that curiosity to lead me into one of the most dynamic corners of today's pharmaceutical industry.
The deeper I looked, the more the story changed. This was no longer simply about a drug. It was about a new therapeutic platform, a new lexicon, a new commercial model, new manufacturing challenges, new scientific disciplines and, increasingly, a new professional community. Like many important innovations in healthcare, radiopharmaceuticals are creating their own ecosystem, one that extends well beyond the laboratory and into imaging centers, manufacturing facilities, hospitals, and business development teams.
I don't know whether radiopharmaceuticals will ultimately become as transformative as monoclonal antibodies, immunotherapy or antibody-drug conjugates. History rarely reveals its biggest shifts in real time. What I do know is that the signals are becoming difficult to ignore. The science is advancing. The investment is accelerating. The infrastructure is expanding. The community is growing.
Sometimes the most interesting discoveries in our industry begin with a simple observation during a research interview. This one began with Pluvicto. It ended with a much broader appreciation for a part of the pharmaceutical industry that I suspect many of us will be spending a great deal more time exploring in the years ahead.
